- Home
- DAWN vs LPTH Comparison
DAWN vs LPTH Comparison
Compare DAWN & LPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- LPTH
- Stock Information
- Founded
- DAWN 2018
- LPTH 1985
- Country
- DAWN United States
- LPTH United States
- Employees
- DAWN N/A
- LPTH N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- LPTH Semiconductors
- Sector
- DAWN Health Care
- LPTH Technology
- Exchange
- DAWN Nasdaq
- LPTH Nasdaq
- Market Cap
- DAWN 658.9M
- LPTH 126.6M
- IPO Year
- DAWN 2021
- LPTH 1996
- Fundamental
- Price
- DAWN $6.90
- LPTH $3.39
- Analyst Decision
- DAWN Strong Buy
- LPTH Strong Buy
- Analyst Count
- DAWN 7
- LPTH 3
- Target Price
- DAWN $31.57
- LPTH $4.67
- AVG Volume (30 Days)
- DAWN 1.3M
- LPTH 152.0K
- Earning Date
- DAWN 07-29-2025
- LPTH 05-15-2025
- Dividend Yield
- DAWN N/A
- LPTH N/A
- EPS Growth
- DAWN N/A
- LPTH N/A
- EPS
- DAWN N/A
- LPTH N/A
- Revenue
- DAWN $161,922,000.00
- LPTH $33,626,969.00
- Revenue This Year
- DAWN $17.98
- LPTH $19.58
- Revenue Next Year
- DAWN $49.50
- LPTH $44.50
- P/E Ratio
- DAWN N/A
- LPTH N/A
- Revenue Growth
- DAWN N/A
- LPTH 2.59
- 52 Week Low
- DAWN $6.08
- LPTH $1.04
- 52 Week High
- DAWN $16.76
- LPTH $4.42
- Technical
- Relative Strength Index (RSI)
- DAWN 58.34
- LPTH 62.11
- Support Level
- DAWN $6.52
- LPTH $2.90
- Resistance Level
- DAWN $7.24
- LPTH $3.18
- Average True Range (ATR)
- DAWN 0.26
- LPTH 0.18
- MACD
- DAWN 0.07
- LPTH -0.02
- Stochastic Oscillator
- DAWN 78.37
- LPTH 92.45
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.